Returns
| Series | 1 week | 1 month | 3 months | 6 months | YTD | 1 year | 3 years (ann.) | 5 years (ann.) | 10 years | Since inception (ann.) |
|---|---|---|---|---|---|---|---|---|---|---|
| Market-price return | -1.33% | +0.25% | +7.23% | +10.43% | +8.37% | +9.02% | +5.04% | -9.64% | — | -3.02% |
| Market-price total return | -1.33% | +0.93% | +9.49% | +15.37% | +15.79% | +19.08% | +16.66% | +0.26% | — | +6.17% |
| NAV return | — | — | — | — | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — | — | — | — | — |
Performance through Oct 14, 2026. Price and NAV returns are simple changes; total returns reinvest each distribution at the series value on its ex-date (first observation on/after). Periods of one year or less are cumulative; longer periods are annualised. Series are built from unadjusted prices plus the distribution record so no distribution is counted twice. Corporate actions: the vendor price series is split-adjusted; rights offerings and mergers are not restated — check Corporate Actions.
Growth of $10,000, five years
Risk statistics
| Statistic | Market price | NAV | Specification |
|---|---|---|---|
| Volatility, 1 year | 0.17% | — | annualised SD of daily total returns, √252 |
| Volatility, 3 years | 0.17% | — | as above |
| Volatility, 5 years | 0.20% | — | as above |
| Maximum drawdown, 3 years | -18.34% | — | peak-to-trough on the total-return index |
| Sharpe ratio, 3 years | 0.72 | — | excess over FRED DGS3MO (window average) (avg 4.52%), annualised |
| Sortino ratio, 3 years | 1.09 | — | downside deviation of excess returns |
| Beta vs. benchmark proxy, 3 years | 0.60 | — | SPY (U.S. equity ETF proxy), daily, aligned dates |
| Correlation, 3 years | 0.54 | — | as above |
| Observations (3y) | 751 | — | minimum 60; rankings require 500 |
Market-price and NAV volatility are different quantities and are never mixed. NAV volatility for funds holding stale-marked or illiquid assets can understate economic risk.
CEF Explorer research page for BlackRock Health Sciences Term Trust. Figures carry their own dates and sources; a discount to NAV does not guarantee convergence or any return. This is not investment advice.